By analyzing its impact on progression-free survival (PFS), overall survival (OS), and treatment response rates, this study provided valuable insights into the role of BTK inhibition in managing MYD88-mutant DLBCL and potentially offered a novel therapeutic strategy for these patients. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.